Regenxbio Inc (RGNX)

$8.14 -0.27 (-3.21%)
Market Cap 399.92M
Revenue (ttm) 83.33M
Net Income (ttm) -227.10M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -272.53%
Debt to Equity Ratio 0.00
Volume 1,019,500
Avg Vol 919,972
Day's Range N/A - N/A
Shares Out 50.62M
Stochastic %K 5%
Beta 1.05
Analysts Strong Sell
Price Target $29.83

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
StocktwitsNews
StocktwitsNews Feb. 20 at 9:57 PM
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy $SRPT $RGNX https://stocktwits.com/news/equity/markets/sarepta-hits-fresh-hurdle-as-court-revives-patent-lawsuit-with-regenxbio-over-muscular-disorder-therapy/cZRNSgQR4xu
0 · Reply
maphere
maphere Feb. 20 at 3:45 PM
$RGNX Regenxbio won an appeal against Serepta /https://www.cafc.uscourts.gov/opinions-orders/24-1408.OPINION.2-20-2026_2650255.pdf
1 · Reply
rando321456
rando321456 Feb. 20 at 9:30 AM
$RGNX Any thoughts on the one trial talk out of the FDA? You guys think we may be able to get away with running one NPDR trial?
1 · Reply
DarkOrb
DarkOrb Feb. 19 at 7:16 PM
$RGNX Seeing rallies in rare disease companies today, RCKT, CAPR, QURE, etc. Is Prasad on the way out? One can hope... https://www.fiercebiotech.com/biotech/white-house-frustration-may-have-fueled-fdas-moderna-change-politico
1 · Reply
rando321456
rando321456 Feb. 19 at 1:56 PM
$RGNX License with Ultragenyx a good bit weaker only covers DTX301 now. I think there's going to have to be something around UX111 before everything is said and done as the University of Minnesota patente are in force until the mid 2030s.
1 · Reply
BRITLS
BRITLS Feb. 18 at 11:30 PM
$RGNX anyone starting to nibble again?
1 · Reply
noepsteintrades
noepsteintrades Feb. 17 at 5:14 PM
$OCUL superior to $RGNX but let's panic
4 · Reply
rando321456
rando321456 Feb. 17 at 12:21 PM
$RGNX Given the apparent failure of the most potent TKIin in durability looking like RGX-314 will increasingly be standing alone in actually reducing treatment burden for severe disease patients.
1 · Reply
rando321456
rando321456 Feb. 14 at 9:31 PM
$RGNX I do think the core to what is happening here is not that this FDA is against gene therapy, the approval of Itvisma would make no sense if that were the case. Rather that it is increasingly dogmatic and inflexible when it comes to accelerated approval. The silver lining is that 202 is flashing the type of data that this FDA may make an exception for based on functional tests , well established natural history, and a superior safety profile. 314 will be about as traditional a readout and BLA filing as one can get aswell.
2 · Reply
BenTheDo
BenTheDo Feb. 14 at 9:13 PM
$RGNX Bears be warned this isn't a long-term short.
0 · Reply
Latest News on RGNX
Regenxbio: Cautiously Bullish After FDA Setbacks

Feb 13, 2026, 6:07 AM EST - 7 days ago

Regenxbio: Cautiously Bullish After FDA Setbacks

FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment

Feb 10, 2026, 8:51 AM EST - 10 days ago

FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment

US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:13 PM EST - 11 days ago

US FDA declines to approve Regenxbio's rare disease drug

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Feb 9, 2026, 4:05 PM EST - 11 days ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

Feb 3, 2026, 3:06 PM EST - 17 days ago

RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

Jan 29, 2026, 6:06 PM EST - 22 days ago

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

FDA Clinical Hold Knocks REGENXBIO Stock

Jan 28, 2026, 12:31 PM EST - 23 days ago

FDA Clinical Hold Knocks REGENXBIO Stock

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:46 AM EST - 23 days ago

US FDA places clinical hold on Regenxbio's gene therapy trials

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

Jan 28, 2026, 7:30 AM EST - 23 days ago

REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs

REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away

Jan 27, 2026, 8:28 AM EST - 24 days ago

REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away

REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 4:25 PM EST - 5 weeks ago

REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

Jan 11, 2026, 3:00 PM EST - 5 weeks ago

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 7:05 AM EST - 2 months ago

REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

REGENXBIO to Participate in Upcoming Investor Conference

Nov 25, 2025, 7:05 AM EST - 3 months ago

REGENXBIO to Participate in Upcoming Investor Conference

REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:16 PM EST - 3 months ago

REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:05 AM EST - 3 months ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

Oct 30, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

Oct 29, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational Highlights

REGENXBIO to Participate in Upcoming Investor Conferences

Oct 15, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

Oct 9, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

Oct 6, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

REGENXBIO Announces Presentation at the World Muscle Society

Sep 29, 2025, 7:05 AM EDT - 5 months ago

REGENXBIO Announces Presentation at the World Muscle Society

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Sep 9, 2025, 6:12 AM EDT - 5 months ago

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 2:05 PM EDT - 5 months ago

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Sep 6, 2025, 8:29 AM EDT - 5 months ago

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Sep 5, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Aug 19, 2025, 12:01 PM EDT - 6 months ago

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 18, 2025, 5:00 PM EDT - 6 months ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 9:11 AM EDT - 7 months ago

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Aug 7, 2025, 7:00 AM EDT - 7 months ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 31, 2025, 7:05 AM EDT - 7 months ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jul 10, 2025, 11:54 AM EDT - 8 months ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 6, 2025, 4:02 PM EDT - 9 months ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 11:43 AM EDT - 9 months ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 5, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

Jun 2, 2025, 7:05 AM EDT - 9 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 19, 2025, 4:05 PM EDT - 9 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 14, 2025, 7:13 AM EDT - 10 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:07 AM EDT - 10 months ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 13, 2025, 7:05 AM EDT - 10 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

StocktwitsNews
StocktwitsNews Feb. 20 at 9:57 PM
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy $SRPT $RGNX https://stocktwits.com/news/equity/markets/sarepta-hits-fresh-hurdle-as-court-revives-patent-lawsuit-with-regenxbio-over-muscular-disorder-therapy/cZRNSgQR4xu
0 · Reply
maphere
maphere Feb. 20 at 3:45 PM
$RGNX Regenxbio won an appeal against Serepta /https://www.cafc.uscourts.gov/opinions-orders/24-1408.OPINION.2-20-2026_2650255.pdf
1 · Reply
rando321456
rando321456 Feb. 20 at 9:30 AM
$RGNX Any thoughts on the one trial talk out of the FDA? You guys think we may be able to get away with running one NPDR trial?
1 · Reply
DarkOrb
DarkOrb Feb. 19 at 7:16 PM
$RGNX Seeing rallies in rare disease companies today, RCKT, CAPR, QURE, etc. Is Prasad on the way out? One can hope... https://www.fiercebiotech.com/biotech/white-house-frustration-may-have-fueled-fdas-moderna-change-politico
1 · Reply
rando321456
rando321456 Feb. 19 at 1:56 PM
$RGNX License with Ultragenyx a good bit weaker only covers DTX301 now. I think there's going to have to be something around UX111 before everything is said and done as the University of Minnesota patente are in force until the mid 2030s.
1 · Reply
BRITLS
BRITLS Feb. 18 at 11:30 PM
$RGNX anyone starting to nibble again?
1 · Reply
noepsteintrades
noepsteintrades Feb. 17 at 5:14 PM
$OCUL superior to $RGNX but let's panic
4 · Reply
rando321456
rando321456 Feb. 17 at 12:21 PM
$RGNX Given the apparent failure of the most potent TKIin in durability looking like RGX-314 will increasingly be standing alone in actually reducing treatment burden for severe disease patients.
1 · Reply
rando321456
rando321456 Feb. 14 at 9:31 PM
$RGNX I do think the core to what is happening here is not that this FDA is against gene therapy, the approval of Itvisma would make no sense if that were the case. Rather that it is increasingly dogmatic and inflexible when it comes to accelerated approval. The silver lining is that 202 is flashing the type of data that this FDA may make an exception for based on functional tests , well established natural history, and a superior safety profile. 314 will be about as traditional a readout and BLA filing as one can get aswell.
2 · Reply
BenTheDo
BenTheDo Feb. 14 at 9:13 PM
$RGNX Bears be warned this isn't a long-term short.
0 · Reply
Steve_TheBull_Rogers
Steve_TheBull_Rogers Feb. 14 at 4:02 AM
$MSTR 126 AVG on commons. Not selling anything until we see at least back to 250-300 Traded this in 2024 from 100s to 400+. I will only touch options on this on Thur/Fri. Mon-Wed they are over priced and not worth the risk/reward. There is more option OI selling on MSTR weekly than TSLA+NVDA combined. Market Makers had to pay out 400M in premium today on calls as Trump/White House comment separated BTC/MSTR from SPY sell off for the 1st time in years! $DKNG PUTS in to earnings was my biggest win this week with 629% put spread return Followed by $RGNX CRL short at 200% Followed by $SPY on Thur via SPX PUTS for 500% on the sell off Traded multiple scalps off open on this today. Will keep trading this on Thur-Fri See you all Tuesday Hope everyone had a great week.
4 · Reply
Lanikai16
Lanikai16 Feb. 13 at 9:00 PM
$RGNX let’s hit the ATM after a disastrous week and a 50% haircut on our stock price… great job Curren!
1 · Reply
rando321456
rando321456 Feb. 13 at 8:44 PM
$RGNX It's still crazy to me that Novartis can come out and say they'll be doing atleast ~2 billion on Itvisma within a couple of years and the market just ignores that. What are these people going to do as those royalties ramp? As far as we know the Zolgensma royalties continue for the foreseeable future aswell.
1 · Reply
TheBlackBerrry
TheBlackBerrry Feb. 13 at 10:13 AM
$RGNX Why isnt this tanking on a 150 mil offering. This was such a horrible short for me. I was forced to cover with a margin call. Hope this company burns
5 · Reply
ThunderCoopersmith
ThunderCoopersmith Feb. 13 at 7:24 AM
$RGNX not a pumper or bot… But folks may wanna check SRXH… Merger incoming for SRXH and recent 14,000,000 share investor buy, etc etc etc just thought this may help us all 🙏🏻🤙🏻🤷🏻‍♂️
0 · Reply
rando321456
rando321456 Feb. 13 at 4:50 AM
$RGNX This IRL on Ultragenyx's MPSIII asset makes me more certain this is a broad FDA problem rather than a problem with how Regenx approached the BLA. Though unfortunately unless they are basically curing duchenne, I think they should abandon their ambition to build out their own commercial infrastructure.
0 · Reply
walterfootball
walterfootball Feb. 13 at 3:36 AM
$RGNX $150 million offering https://www.stocktitan.net/sec-filings/RGNX/424b5-regenxbio-inc-prospectus-supplement-debt-securities-185ed4ac500f.html
0 · Reply
ignoreo
ignoreo Feb. 13 at 1:15 AM
$MRNA $REPL $QURE $CAPR $RGNX its strange to think about but by the time vinay prasad's conquest is over, he will have killed more americans than hitler. and it wont even be close
1 · Reply
TrialWatcher
TrialWatcher Feb. 12 at 9:09 PM
$RGNX congrats on the 150m offering
0 · Reply
ccledez
ccledez Feb. 12 at 4:16 PM
$RGNX 3 days later 200% later Easy call. They had a clinical hold.
1 · Reply
Heap_Of_Funk
Heap_Of_Funk Feb. 12 at 2:20 PM
$SRPT $RNA $CAPR $SLDB $RGNX good question. The answer is simple When Doug starts taking the naked shorting and manipulation here by short hedge funds seriously and When Doug starts taking a proactive approach and creating catalysts such as discussions of a strategic sale seriously. Its all Doug
0 · Reply
free2dream
free2dream Feb. 12 at 2:15 PM
$SRPT compare to $RNA at $12B market cap, no sales and samy hype as $CAPR $SLDB $RGNX . SAREPTA SHOULD BE TRADING AT $12-15B market cap on $2B sales and very exciting pipeline. WHEN WILL THE INVESTORS WAKE THE FUCK UP AND PAY ATTENTION TO THIS ?
0 · Reply